Skip to main content

Table 4 Registered clinical trials for the treatment of malignant tumors using CRISPR/Cas9 modified adoptive cell therapy. Data from https://clinicaltrials.gov/ (last updated 14/12/2021)

From: Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

Clinical Trial Number

Phase

Target Gene

Cancer Type

Cell Type

Sponsor/Country

Recruitment Status

NCT03747965

Phase 1

PDCD1-KO

Adult Solid Tumor

Mesothelin-directed CAR-T cells

China

Recruiting

NCT03044743

Phase 1/2

PDCD1-KO

Stage IV Gastric Carcinoma

Stage IV Nasopharyngeal Carcinoma

T-Cell Lymphoma Stage IV

Stage IV Adult Hodgkin Lymphoma

Stage IV Diffuse Large B-Cell Lymphoma

EBV-CTL cells

China

Recruiting

NCT03081715

Phase 1

PDCD1-KO

Esophageal Cancer

Primary T-cells

China

Completed

NCT02793856

Phase 1

PDCD1-KO

Metastatic Non-small Cell Lung Cancer

Primary T-cells

China

Completed

NCT04417764

Phase 1

PDCD1-KO

Advanced Hepatocellular Carcinoma

Primary T-cells

China

Recruiting

NCT04426669

Phase 1/2

CISH-KO

Gastrointestinal Epithelial Cancer

Gastrointestinal Neoplasms

Tract Cancer

Gastrointestinal Cancer

Colo-rectal Cancer

Pancreatic Cancer

Gall Bladder Cancer

Colon Cancer

Esophageal Cancer

Stomach Cancer

TILs

The United States

Recruiting

NCT03057912

Phase 1

CISH-KO

Human Papillomavirus-Related Malignant Neoplasm

TILs

China

Not yet recruiting

NCT03399448

Phase 1

TRAC, TRBC, PDCD1-KO

Multiple Myeloma Melanoma

Synovial Sarcoma

Myxoid/Round Cell Liposarcoma

NY-ESO-1 redirected autologous T cells

The United States

Completed

NCT03545815

Phase 1

TRAC, TRBC, PDCD1-KO

Solid Tumor

anti-mesothelin CAR-T cells

China

Recruiting

NCT03166878

Phase 1/2

TRAC, TRBC, B2M-KO

B Cell Leukemia

B Cell Lymphoma

UCART019

China

Recruiting

NCT05037669

Phase 1

B2M, CIITA, TRAC-KO

Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

CD19-specific CAR-T cells

The United States

Not yet recruiting

NCT04037566

Phase 1

HPK1-KO

Acute Lymphoblastic Leukemia in Relapse

Acute Lymphoblastic Leukemia Refractory

Lymphoma, B-Cell CD19 Positive

XYF19 CAR-T cells

China

Recruiting

NCT04557436

Phase 1

CD52 and TRAC-KO

B Cell Acute Lymphoblastic Leukemia

CD19-specific CAR-T cells

The United Kingdom

Recruiting

NCT04976218

Phase 1

TGFβR-KO

Advanced Biliary Tract Cancer

CAR-EGFR T cells

Unknown

Not yet recruiting

NCT04767308

Early Phase 1

CD5-KO

CD5+ Relapsed/Refractory Hematopoietic Malignancies

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Diffuse Large B-cell Lymphoma

Follicular Lymphoma

Peripheral T-cell Lymphomas

CT125A cells

Unknown

Not yet recruiting

NCT04244656

Phase 1

Unknown

Multiple Myeloma

Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120)

The United States

Recruiting

NCT04438083

Phase 1

Unknown

Renal Cell Carcinoma

Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130)

The United States

Australia

Canada

Netherlands

Recruiting

NCT04502446

Phase 1

Unknown

T Cell Lymphoma

Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130)

The United States

Australia

Canada

Recruiting

NCT04035434

Phase 1

Unknown

B-cell Malignancy Non-Hodgkin Lymphoma

B-cell Lymphoma

Adult B Cell Acute Lymphoblastic Leukemia

CD19-specific CAR-T cells (CTX110)

The United States

Australia

Canada

Germany

Spain

Recruiting

NCT04637763

Phase 1

Unknown

Lymphoma

Non-Hodgkin Lymphoma Relapsed

Non-Hodgkin Lymphoma Refractory

B-Cell Non-Hodgkin Lymphoma

CD19-specific CAR-T cells (CB-010)

The United States

Recruiting

NCT03398967

Phase 1/2

Unknown

B Cell Leukemia

B Cell Lymphoma

Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells

China

Recruiting

NCT05066165

Phase 1/2

Unknown

Acute Myeloid Leukemia

WT1-directed TCR T cells

The United States

The United Kingdom

Not yet recruiting

NCT04244656

Phase 1

Unknown

Multiple Myeloma

Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120)

The United States

Australia

Canada

Spain

Recruiting